IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
Retrieved on:
Monday, November 6, 2023
Data Management, Biotechnology, Technology, Professional Services, Health, Health Technology, Research, Data Analytics, Software, Science, Clinical Trials, NYSE, NBA, IQV, NBA scoring leaders, Industry Dive, National Basketball Association, Nike Vaporfly and Tokyo 2020 Olympics Controversy, Population health, Life, 2020 NBA Bubble, COVID-19, Patient, IQVIA, Management, Nursing
IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.
Key Points:
- IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.
- Christina Mack and her fellow honorees inspire advancements by guiding their teams, supporting their patients, and propelling their organizations’ missions forward.
- We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.
- The work we do together is pushing new boundaries in science and technology to improve population health and patient outcomes,” said Dr. Mack.